Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data
Company Posts Solid Q2 Sales Despite REGEN-COV Drop
Executive Summary
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.
You may also be interested in...
The COVID-19 Market: Keeping Up With The Changing Landscape
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.
Gilead Oncology Sales Take Off As Veklury’s Come Down To Earth
As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.
Dupixent Sales Surge Lifts Sanofi’s Guidance, Markets Still 'Underpenetrated'
The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.